Table 4.

Treatment-emergent adverse events reported in ≥2 patients in any dosing regimen (safety analysis dataset)

System organ class Preferred term, n (%)	Dosing regimen			Overall
	Veliparib	Veliparib	Placebo
	200 mg	400 mg
	N = 47	N = 47	N = 46	N = 47
Gastrointestinal disorders
Abdominal pain	2 (4.3)	2 (4.3)	0	3 (6.4)
Constipation	0	1 (2.1)	2 (4.3)	3 (6.4)
Diarrhea	1 (2.1)	3 (6.4)	0	3 (6.4)
Nausea	6 (12.8)	4 (8.5)	3 (6.5)	11 (23.4)
Vomiting	2 (4.3)	4 (8.5)	0	6 (12.8)
General disorders and administration site conditions
Fatigue	2 (4.3)	3 (6.4)	2 (4.3)	7 (14.9)
Metabolism and nutrition disorders
Decreased appetite	0	1 (2.1)	2 (4.3)	3 (6.4)
Dehydration	2 (4.3)	0	0	2 (4.3)
Hypomagnesemia	0	0	2 (4.3)	2 (4.3)
Musculoskeletal and connective tissue disorders
Back pain	0	2 (4.3)	0	2 (4.3)
Myalgia	4 (8.5)	1 (2.1)	1 (2.2)	5 (10.6)
Neck pain	0	2 (4.3)	0	2 (4.3)
Nervous system disorders
Dizziness	0	3 (6.4)	1 (2.2)	4 (8.5)
Dysgeusia	0	2 (4.3)	0	2 (4.3)